Abstract The Japanese surveillance committee conducted the first nationwide surveillance of antimicrobial susceptibility patterns of uropathogens responsible for female acute uncomplicated cystitis at 43 hospitals throughout Japan from April 2009 to November 2010. In this study, the causative bacteria (Escherichia coli and Staphylococcus saprophyticus) and their susceptibility to various antimicrobial agents were investigated by isolation and culturing of bacteria from urine samples. In total, 387 strains were isolated from 461 patients, including E. coli (n = 301, 77.8 %), S. saprophyticus (n = 20, 5.2 %), Klebsiella pneumoniae (n = 13, 3.4 %), and Enterococcus faecalis (n = 11, 2.8 %). S. saprophyticus was significantly more common in premenopausal women (P = 0.00095). The minimum inhibitory concentrations of 19 antibacterial agents used for these strains were determined according to the Clinical and Laboratory Standards Institute manual. At least 87 % of E. coli isolates showed susceptibility to fluoroquinolones and cephalosporins, and 100 % of S. saprophyticus isolates showed susceptibility to fluoroquinolones and aminoglycosides. The proportions of fluoroquinolone-resistant E. coli strains and extendedspectrum b-lactamase (ESBL)-producing E. coli strains were 13.3 % and 4.7 %, respectively. It is important to confirm the susceptibility of causative bacteria for optimal antimicrobial therapy, and empiric antimicrobial agents should be selected by considering patient characteristics and other factors. However, the number of isolates of fluoroquinolone-resistant or ESBL-producing strains in gram-negative bacilli may be increasing in patients with urinary tract infections (UTIs) in Japan. Therefore, these data present important information for the proper treatment of UTIs and will serve as a useful reference for future surveillance studies.
Introduction
Urinary tract infections (UTIs) are among the most common diseases caused by bacteria in adults and should be treated with effective antimicrobial chemotherapy. However, the treatment of UTIs is becoming more difficult because of increasing bacterial resistance to antimicrobial agents.
Many surveys on antimicrobial susceptibility of the organisms have been performed in Japan and the results are widely used as a guide for selecting appropriate antibacterial therapy [1] [2] [3] [4] . To investigate comprehensively the antimicrobial susceptibility and resistance of bacterial urinary pathogens, the Japanese Society of Chemotherapy (JSC) established a nationwide surveillance network in 2006. The first survey was conducted during the period from January to December in 2008, and we reported the trend of antimicrobial susceptibilities of bacterial species isolated from patients with UTIs [4] . To use antimicrobials appropriately, information on the antibiotic susceptibility of the pathogens isolated from UTIs is of particular value. Therefore, the distribution of causative bacteria and their susceptibility to various antimicrobial agents were investigated by a survey of urine specimens from patients with acute uncomplicated cystitis (AUC).
Here we report a study of nationwide surveillance for AUC conducted by the JSC, the Japanese Associations for Infectious Diseases (JAID), and the Japanese Society for Clinical Microbiology (JSCM). The purpose of this study was to investigate the antimicrobial susceptibility of the pathogens isolated from AUC by a nationwide survey, and to record the data for future comparison with antibioticresistant organisms obtained by periodic surveillance.
Materials and methods
The Japanese surveillance committee
The Japanese surveillance committee, consisting of the JSC, JAID, and JSCM, conducted the first nationwide surveillance of antimicrobial susceptibility patterns of uropathogens responsible for female AUC. The study protocol was prepared by the working group and accepted by the governing board of the Japanese surveillance committee. Ethics approval was the responsibility of each facility. The facilities that did not have an ethical committee submitted this study to the ethical committee of the specific nonprofit organization CREC net, Kitakyushu, Japan, which approved it. The clinicians who participated in this study explained the purpose of the study to the patients orally or through written documents and obtained the written consent of each patient. All data were reported to the study database with patient information remaining anonymous and confidential.
Patients
Among the patients with AUC who visited any of the 43 institutions (Table 1) across Japan from April 2009 to   November 2010, those who had symptoms such as micturitional pain, frequent urination, urgency, or suprapubic  pain, and who met the following inclusion criteria were  enrolled. Inclusion criteria were set in accordance with the guidelines for clinical trials on genitourinary tract infections, version 1 [5] . Patients with AUC were required to be female, aged 16 years or older, lacking underlying urinary tract disease and/or factors contributing to the onset, worsening, or prolongation of urinary tract infection; diabetes mellitus, malignancy under treatment, cerebrovascular disease requiring assistance, and corticosteroid or immunosuppressant therapy. One or more of the following was also required: pyuria confirmed by a reagent strip; C5 white blood cells (WBCs) per high-power field (hpf) on microscopy of urine sediment, or C10 WBCs/mm 3 measured by flow cytometry or a counting chamber; and bacteriuria C10 3 colony-forming units (cfu)/ml (for midstream urine, C10 4 cfu/ml).
Bacteriological examination

Collection of urine samples and bacterial strains
Urine samples were collected from patients with AUC as midstream urine or via a catheter in accordance with the guidelines for clinical trials on genitourinary tract infections, version 1 [5] . They were spread on Slideculture U (Eiken Chemical, Tokyo, Japan) by the investigators and were sent on the same day to a central bacteriological laboratory (the Research Center for Anti-infective Drugs of the Kitasato Institute, Kanagawa, Japan) for testing. Bacterial strains received from the medical institutions were cultured at 37°C for 16-24 h, and isolates were identified, counted, and stored at -80°C for future investigation.
Susceptibility testing and determination of the minimal inhibitory concentration (MIC)
MICs against two main causative organisms of AUC, Escherichia coli and Staphylococcus saprophyticus, were measured by the broth microdilution method according to the guidelines of the Clinical and Laboratory Standards Institute (CLSI) set out in standards M7-A7 [6] , M100-S17 [7] and M45-A [8] 
Quality control
Accuracy of determination of the MIC of antimicrobial agents was controlled according to the recommendations of the CLSI, using the following control strains: E. coli ATCC25922 for E. coli and S. aureus ATCC29213 for S. saprophyticus. E. coli ATCC35218 was used as a control strain for the MIC determination of b-lactam antibiotics combined with b-lactamase inhibitors.
Antibacterial agents
The susceptibilities of E. coli strains were tested for the following 17 antimicrobial agents: one penicillin, ampicillin (ABPC; Meiji); one penicillin in combination with b-lactamase inhibitors, clavulanic acid-amoxicillin (CVA/AMPC; Glaxo SmithKline); five oral cephalosporins, cefaclor (CCL; Shionogi), cefpodoxime (CPDX; Daiichi-Sankyo), cefdinir (CFDN; Astellas Pharma), cefditoren (CDTR; Meiji), and cefcapene (CFPN; Shionogi); one penem, faropenem(FRPM; Astellas); two aminoglycosides, gentamicin (GM; Shionogi) and amikacin (AMK; Banyu); five fluoroquinolones, ciprofloxacin (CPFX; BayerYakuhin), levofloxacin (LVFX; Daiichi-Sankyo), tosufloxacin (TFLX; Toyama), prulifloxacin (PUFX; Kyorin Pharmaceutical), and sitafloxacin (STFX; DaiichiSankyo); and two others, fosfomycin (FOM; Meiji) and sulfamethoxazole/trimethoprim (ST; Shionogi).
The susceptibilities of S. saprophyticus strains were tested for 17 antimicrobial agents in the same manner as the E. coli testing, as well as two glycopeptides: vancomycin (VCM; Shionogi) and teicoplanin (TEIC; Astellas).
Detection of b-lactamase production
The Cica-beta test (Kanto Chemical, Tokyo, Japan), a recently developed, rapid method for the detection of extended-spectrum b-lactamase (ESBL)-producing E. coli, was used by directly scraping a colony and applying it on the disk [9, 10] . These tests were conducted according to the reference manual supplied by the manufacturer.
Investigation of patient characteristics
On the day of urine collection, investigators interviewed each patient to obtain data on the following characteristics: age, menopausal status, and method for collection of urine sample. The patient's clinical data and the bacterial species identified were recorded on a standardized data sheet. The microbiological data obtained were analyzed according to the clinical settings and profiles of the patients.
Assessment
Assessment of antimicrobial susceptibility
The antimicrobial susceptibility of the pathogens was categorized into three classes, namely, susceptible, intermediate, or resistant, according to the MIC breakpoints recommended by CLSI standards M100-S18 [11] , and the susceptibility rate was defined as the percentage of susceptible strains. For agents not described in the CLSI guidelines, breakpoints were set based on those for similar agents. The breakpoints for LVFX in the CLSI guidelines are B2 lg/ml (susceptible), 4 lg/ml (intermediate), and C8 lg/ml (resistant), and those for CPFX are B1, 2, and C4 lg/ml, respectively. Thus, the corresponding values for TFLX, PUFX, and STFX were likewise set at B1 lg/ml (susceptible), 2 lg/ml (intermediate), and C4 lg/ml (resistant). The breakpoints for CPDX in the CLSI guidelines are B2 lg/ml (susceptible), 4 lg/ml (intermediate), and C8 lg/ml (resistant), and those for CFDN are B1, 2, and C4 lg/ml, respectively. Thus, the corresponding values for CDTR, CFPN, and FRPM were set at B1 lg/ml (susceptible), 2 lg/ml (intermediate), and C4 lg/ml (resistant). Quinolone resistance was defined as that equivalent to the MIC of LVFX for E. coli, C4 lg/ml.
Assessment of the detection rate of E. coli and S. saprophyticus by menopausal status
The detection rates of E. coli and S. saprophyticus were statistically compared between premenopausal and postmenopausal patients using the Fisher's exact test. A P value \ 0.05 indicates statistical significance.
Results
Study population and patient characteristics
A total of 461 urine samples were registered from 43 Japanese hospitals during the study period, among which 364 samples were included in the analysis and 97 samples were excluded. The backgrounds of the patients are shown in Table 2 . All the patients with AUC were female. The mean age (± standard deviation) was 49.1 ± 20.2 years, with elderly patients aged C70 years accounting for 21.5 % of the urine samples. The majority of the urine samples of samples were collected as midstream urine (92.6 %). Among the women with AUC, 47.3 % were postmenopausal.
Causative bacteria
The causative bacteria are shown in Table 3 . The number of strains isolated as causative bacteria from 461 patients with AUC was 387. Major causative bacteria included 301 E. coli (77.8 %), 20 S. saprophyticus (5.2 %), 13 Klebsiella pneumoniae (3.4 %), 11 Enterococcus faecalis (2.8 %), and 8 Streptococcus agalactiae (2.1 %). Gram-negative and grampositive bacteria, respectively, accounted for 86.3 % (334 strains) and 13.4 % (52 strains) of all strains. The gramnegative/gram-positive ratio of the isolates was 13:2.
A stratified analysis of the detection rate of pathogens by menopausal status was performed. Among the women with AUC whose causative bacterium was E. coli (median age, 53 years) or S. saprophyticus (median age, 24.5 years), 49.2 % and 89.5 %, respectively, were premenopausal. The results showed that infection with S. saprophyticus was significantly more common in premenopausal women (P = 0.00095) ( Table 4) .
Susceptibility profile
The MIC distribution, i.e., MICs for 50 % and 90 % of the organisms (MIC 50 and MIC 90 values, respectively), is shown in Table 5 . The susceptibility rate based on the MIC breakpoints set by CLSI for each antimicrobial agent are stratified by E. coli, ESBL-producing E. coli, and S. saprophyticus in Figs. 1, 2, and 3, respectively.
Antimicrobial susceptibility of Escherichia coli (301 strains)
The susceptibility rate of 301 E. coli strains isolated from patients with AUC for oral cephalosporins was high (92.0 % for CCL, 92.4 % for CPDX, 92.7 % for CFDN, 93.7 % for CDTR, and 94.0 % for CFPN), with the highest susceptibility rate seen with CFPN (Fig. 1) . The MIC 90 of a penicillin derivative (ABPC) in these E. coli strains was C256 lg/ml, whereas the MIC 90 of a penicillin derivative in the presence of the b-lactamase inhibitors (CVA/AMPC) decreased to 8 lg/ml ( Table 5 ). The MIC 90 of five oral cephalosporins and one oral penem (FRPM) was 1-4 lg/ml and, therefore, all of them were active against E. coli (Table 5 ). The susceptibility rate for all fluoroquinolones was also high (87.7 % for LVFX, 98.0 % for STFX, 87.7 % for CPFX, 91.5 % for TFLX), with the highest susceptibility rate seen with STFX (Fig. 1) . The MIC 90 of five fluoroquinolones in these E. coli strains ranged from 1 to C32 lg/ml, and the percentage of resistant strains was 12.3 %. Susceptibility to two aminoglycosides (GM and AMK) was very high, with susceptibility rates of 93.7 % and 100 %, respectively. FOM was also very high with susceptibility rates of 100 % (Fig. 1) .
Fourteen ESBL-producing strains (14/301; 4.7 %) were detected. In these strains, the MIC 90 of ABPC and five oral cephalosporins ranged from 64 to C256 lg/ml (Table 6) , and the susceptibility rate for all antimicrobials was decreased except for CVA/AMPC, FRPM, aminoglycosides, FOM, and ST. Remarkably, the ratio of resistant strains for ABPC and oral cephalosporins was 100 % (Fig. 2) . 
Antimicrobial susceptibility of Staphylococcus saprophyticus (20 strains)
The 20 S. saprophyticus strains isolated from patients with AUC showed variable susceptibility to oral b-lactam antibiotics. The MIC 90 of two penicillin derivatives (ABPC and CVA/AMPC) was 0.5-2 lg/ml, and that of five oral cephems and one oral penem (FRPM) was 0.5-4 lg/ml. Therefore, all were active against S. saprophyticus, except for two cephalosporins (CPDX and CFPM) ( Table 7 ). The MIC 90 of fluoroquinolones in S. saprophyticus ranged from B0.06 to 0.5 lg/ml, and fluoroquinolone-resistant strains were not seen ( Table 7 ). All the S. saprophyticus strains were susceptible to two aminoglycosides (GM and AMK) and two glycopeptides (VCM and TEIC) (Fig. 3) . On the other hand, the MIC 50 and MIC 90 of FOM were 64 and C256 lg/ml, respectively.
Discussion
AUC accounts for the greatest number of UTIs, particularly among young, sexually active, and postmenopausal women. A previous study has reported that 50-60 % of * C128 lg/ml, ** C32 lg/ml women experience at least one UTI in their lifetime [12] . According to the guidelines for antimicrobial use published by JAID and JSC in 2005, the standard antimicrobial regimen for the treatment of AUC is 3 days of therapy with fluoroquinolones or 7 days with b-lactam antibiotics. However, recent reports have indicated increased isolation of fluoroquinolone-resistant or ESBL-producing gramnegative bacilli in patients with UTIs worldwide [4, [13] [14] [15] . Striking evidence is seen in the increase of E. coli strains resistant to fluoroquinolones, which could reflect the overuse of quinolones for treatment of communityacquired UTIs. It has been suggested that quinolone resistance is higher in developing countries, as opposed to that in developed nations, because of the use of less active quinolones, such as nalidixic acid, or the use of ineffective doses, which result in selection of mutant isolates [16] . Under such circumstances, to use antimicrobial agents appropriately, it is important to confirm the susceptibility profile of causative bacteria and to select the correct agents. Accordingly, we investigated the distribution of causative bacteria and their susceptibility profile to 19 antimicrobial agents in patients with AUC diagnosed according to the Japanese guidelines for clinical trials on genitourinary tract infections [5] .
The microbial etiology of uncomplicated UTIs has been regarded as well established and reasonably consistent, although with a noticeable increase in antimicrobial resistance in recent years. E. coli remains the predominant uropathogen isolated in acute uncomplicated UTIs, followed by S. saprophyticus [17, 18] . E. coli comprised the largest number (301 of 387; 77.8 %) of isolates in the study. When we compare these data to mega-surveillance data in other countries [13, 14, 19] , the distribution of causative bacteria for uncomplicated UTIs was similar to that in published studies. On the other hand, the present isolation rate of S. saprophyticus was slightly higher (20 of 387; 5.2 %) than that in recent worldwide studies [13, 14] . S. saprophyticus is second only to E. coli as the most frequent causative organism of AUC in women. As approximately one-half of the female patients with AUC were premenopausal, a stratified analysis on the detection rate of E. coli and S. saprophyticus by menopausal status was performed. The results showed that the detection rate of E. coli was 72.4 % in 240 premenopausal women (147/ 203 strains) and 84.0 % in 218 postmenopausal women (152/181 strains). No statistical difference was observed (P = 0.0570). On the other hand, the results showed that the detection rate of S. saprophyticus was 8.4 % in 240 premenopausal women (17/203 strains) and 1.1 % in 218 postmenopausal women (2/181 strains), and a statistical difference was observed (P = 0.00095). These results are consistent with the previous report that the majority of UTIs by S. saprophyticus occur in young sexually active women [20] . Therefore, this study highlights two major bacterial uropathogens: E. coli and S. saprophyticus. In Japan, fluoroquinolone-resistant E. coli has been noted as a clinical problem. Because various bacteria can cause UTIs, fluoroquinolones may be appropriate for empirical therapy because of their wide spectrum of activity. However, it has also been reported that a major risk factor for fluoroquinolone-resistant E. coli is recent (within 1 month) fluoroquinolone use and recurrent UTIs [4, 21] . In this study, the proportion of fluoroquinoloneresistant or intermediate E. coli isolated from AUC was 12.3 %, slightly higher than the rate of 8.2 % from our recent study [4] . When STFX (98.0 %) was excluded, the fluoroquinolones susceptibility rates of E. coli isolated from AUC ranged from 87.3 % to 87.7 %, slightly lower than the rates of 92.0-94.0 % for oral cephalosporins. STFX shows high activity against bacteria resistant to existing fluoroquinolones and has been available since 2008 [22] . On the other hand, the susceptibility rates of E. coli were 99.0 % for FRPM and 100 % for FOM, so both antimicrobials had rates similar to that of STFX. In the guidelines for antimicrobial use published by JSC and JAID, 3 days of therapy with fluoroquinolones or 7 days with b-lactam antibiotics is recommended for empirical therapy of AUC, although these regimens should be reevaluated in the next decade. Low-dose fluoroquinolones should no longer be used because of the potential for emergence of resistance [23] . Thus, the results presented herein suggest the appropriateness of such an empirical treatment. Furthermore, STFX, oral cephalosporins, FRPM, or FOM should be chosen when E. coli is the likely cause.
Another problem is the emergence of multi-antibioticresistant E. coli. Fluoroquinolone-resistant E. coli strains isolated from patients with UTIs are frequently resistant to other antimicrobials. Production of ESBL in E. coli largely contributes to resistance to the third-and fourth-generation cephalosporins. This study found 14 ESBL-producing E. coli (4.7 %), which is about four times higher than that of previous data in Japan, which showed only 4 ESBLproducing E. coli (1.1 %) among the 351 strains isolated in 2003 [24] . Against these ESBLs, the rates of susceptibility were 100 % to AMK and FOM, and 0 % to ABPC, CCL, CPDX, CFDN, CDTR, and CFPN. Thus, the frequency of ESBL-producing E. coli from AUC is increasing, although as yet it is not very high. However, the use of many different classes of antibiotics in the same patient may cause the mutants to be resistant to structurally and functionally diverse antibiotics [25] . An important factor impacting the high frequency of antimicrobial-resistant bacteria may be the aberrant use of antibiotics. A urine culture and an antimicrobial susceptibility test of the urine specimen seem to be essential for diagnosing the disease, recommending the use of appropriate antibiotics, and reducing the number of antibiotic-resistant uropathogens.
S. saprophyticus is uniquely associated with uncomplicated UTI in humans. The prevalence of colonization of S. saprophyticus of the urogenital tract among healthy women was 6.9 %; the most common site of colonization was the rectum (40 %) [26] . UTI caused by S. saprophyticus is associated with recent sexual intercourse and occurs more often during late summer and fall [27] . The microorganisms colonize the human gastrointestinal tract, particularly during the gastroenteritis season in the summer and fall, which likely accounts for the observed seasonal variation in the incidence of UTI caused by S. saprophyticus [20] . In addition, significantly more patients infected with S. saprophyticus complained of dysuria, urinary frequency, and back pain than did patients infected with E. coli [28] . S. saprophyticus strains studied here showed high susceptibility to fluoroquinolones and aminoglycoside antibiotics compared to other b-lactams (Fig. 3) , and marked resistance to CPDX, CFPM, and FOM, with a resistance ranging from 35 % to 65 % (Fig. 1) . Other antibiotics found to be effective against S. saprophyticus were vancomycin and teicoplanin, as none of the strains showed resistance to them. We suppose that fluoroquinolones and aminoglycoside antibiotics could be used to treat AUC in young sexually active women from the results of this study. However, recurrence of UTI caused by to S. saprophyticus is common. In addition, single-dose therapy with fluoroquinolones is less effective than a 3-day course [29] .
Conclusions
AUC is of significance in the community because of its high prevalence. To use antimicrobial agents appropriately, it is important to confirm the susceptibility profile of causative bacteria before treatment. When empiric therapy is required, careful consideration of patient characteristics appears to be important for choosing the correct agents. However, the increasing prevalence of UTIs and antibioticresistant bacteria has made empiric antibiotic treatment increasingly more difficult. In the next decade, an increasing number of isolates of fluoroquinolone-resistant pathogens, as well as ESBL-producing strains, could be a serious clinical problem. It is important that physicians are aware of regional resistance ratios before initiating empiric antimicrobial therapy for the treatment of AUC. The data obtained from this study provide essential information about the trends of antimicrobial-resistant pathogens and will help determine the optimal treatment for patients with AUC. In addition, the data are retained for comparison with the isolation of antibiotic-resistant organisms from periodic future surveillance.
